NRX Pharmaceuticals
NRXP
28 hedge funds and large institutions have $14.2M invested in NRX Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
17% more funds holding
Funds holding: 24 → 28 (+4)
9% more capital invested
Capital invested by funds: $13M → $14.2M (+$1.13M)
2.29% less ownership
Funds ownership: 19.97% → 17.68% (-2.3%)
22% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$2.73M |
| 2 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$984K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$523K |
| 4 |
BFG
Bleakley Financial Group
Fairfield,
New Jersey
|
+$315K |
| 5 |
GRP
Global Retirement Partners
San Rafael,
California
|
+$105K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$624K |
| 2 |
Renaissance Technologies
New York
|
-$423K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$401K |
| 4 |
Jane Street
New York
|
-$94.8K |
| 5 |
Two Sigma Investments
New York
|
-$93.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LFG
26
Larson Financial Group
St Louis,
Missouri
| $60 | – | – | – |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| $3 | -$867 | -323 | -100% |
|
|
SPIA
28
Steward Partners Investment Advisory
New York
| $3 | +$3 | +1 | New |
|
|
29
Marshall Wace
London,
United Kingdom
| – | -$624K | -189,136 | Closed |
|
|
30
Renaissance Technologies
New York
| – | -$423K | -128,175 | Closed |
|
|
CWA
31
Carolina Wealth Advisors
Myrtle Beach,
South Carolina
| – | -$165 | -50 | Closed |
|
NRXP Hedge Fund Activity: Q4 2025 in Review
28 of the 8,252 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals (NRXP) for Q4 2025, worth a combined $14.2M — up 8.6% from $13M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new NRXP positions and 3 closed out — a net gain of 4 holders — while 7 added to existing stakes and 9 trimmed.
The largest buyer was Anson Funds Management, adding an estimated $2.73M. The largest seller was Marshall Wace, exiting entirely with an estimated $624K sold.
- 28 institutional investors held NRX Pharmaceuticals (NRXP) as of Q4 2025, up from 24 in Q3 2025.
- Funds reported $14.2M of NRX Pharmaceuticals stock for Q4 2025, up 8.6% quarter-over-quarter.
- 7 funds opened new NRX Pharmaceuticals positions in Q4 2025 and 3 closed out, a net change of +4 holders.
- The largest NRX Pharmaceuticals buyer in Q4 2025 was Anson Funds Management, an estimated $2.73M added.
- The largest NRX Pharmaceuticals seller in Q4 2025 was Marshall Wace, an estimated $624K sold.
Based on aggregated 13F filings for Q4 2025.